See and Treat LEEP

E.J. Mayeaux, Jr., M.D.
Associate Professor of Family Medicine
Clinical Associate Professor of Obstetrics and Gynecology
Louisiana State University Medical Center - Shreveport, Louisiana

Another potential use of the LEEP procedure is diagnosing and treating some patients in a single visit. The so-called "see and treat method" offers advantages and disadvantages over the currently recommended method of standard therapeutic LEEP after directed colposcopic biopsy.34 It has been proposed for patients with evidence of high grade dysplasia (not LGSIL or HPV lesions) on Pap smear cytology with visible lesions and an adequate colposcopic exam. It should not be used when colposcopic findings are equivocal or suggestive of invasive cancer.

A potential advantage of LEEP is that diagnosis and therapy can be done in one clinic visit with one pelvic exam. It may also provide better tissue samples than punch biopsies, leading to better histological diagnosis. Patient discomfort and loss of follow-up before treatment, with its concomitant risk of cancer, also may be decreased. In addition, patient's anxiety while awaiting pathology results and anticipating treatment may be lessened or eliminated.

The major concern with this approach is that the procedure may be performed on patients who do not need it (Table 6). Approximately 5 to 47 percent of patients could be treated unnecessarily (including HPV lesions without a SIL). 31, 32, 34, 44, 45 The histology fees tend to be higher with this method, and a patient with HPV effect, LGSIL, or normal tissue will pay significantly more and be exposed to unnecessary risk. The study by Roland, et al., demonstrated that traditional colposcopy followed by treatment was more cost-effective than "see and treat" LEEP. 45 The morbidity and mortality from the possibility of missing invasive disease must be weighed against the potential cost and morbidity of the procedure.


Table 6. "See and Treat" LEEP effects from the English language literature.

Ref.  # in   Over- Under- Pap Smear      Follow-up
      Study  tx    tx*    Normalization  Time 
--------------------------------------------------
6     1000   -     5.3%   95.9%          4 months
31    236    14%   1.7 %  91.3%          4-6 months
32    185    32.5% 0.5%   93.3%          6 months
33    424    -     -      81%            4.7 years
34    1000   4.7%  0.5%   96.7%          8 months
44    114    14%   0.9%   -              none
45    46.7   46.7% -      -              none

* Incomplete excision or presence of cancer.

Return to LEEP Atlas Table of Contents

Return to LSUMC-S Clinical and Academic Medicine Home Page

Return to the LSUMC-S Home Page.


LSUMC-S Family Medicine. Write to us if you have comments or questions! EMayea@lsuhsc.edu